KNSA Kiniksa Pharmaceuticals Ltd

  1. Stocks
  2. Healthcare
  3. NASDAQ: KNSA

Price (delayed)

$49.32

Market cap

$3.79B

P/E Ratio

50.33

Dividend/share

N/A

EPS

$0.98

Enterprise value

$3.61B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 96

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa's portfolio of ...

Highlights
The P/E is 70% below the last 4 quarters average of 160.3
KNSA's gross profit has surged by 63% year-on-year and by 12% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.kiniksa.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of KNSA

KNSA stock price

How has the Kiniksa Pharmaceuticals stock price performed over time
Intraday
3.07%
1 week
-2.99%
1 month
-14.4%
1 year
70.78%
YTD
19.56%
QTD
2.43%

Financial performance

How have Kiniksa Pharmaceuticals's revenue and profit performed over time
Revenue
$754.05M
Gross profit
$673.44M
Operating income
$93.22M
Net income
$73.06M
Gross margin
89.3%
Net margin
9.7%
KNSA's gross profit has surged by 63% year-on-year and by 12% since the previous quarter
Kiniksa Pharmaceuticals's revenue has surged by 57% YoY and by 11% QoQ
KNSA's net income is up by 24% since the previous quarter
KNSA's operating income is up by 21% since the previous quarter

Price vs fundamentals

How does KNSA's price correlate with its fundamentals

Growth

What is Kiniksa Pharmaceuticals's growth rate over time

Valuation

What is Kiniksa Pharmaceuticals stock price valuation
KNSA P/E details
P/E
50.33
P/B
6.23
P/S
5
EV/EBIT
34.1
EV/EBITDA
32.41
EV/Sales
4.79
The P/E is 70% below the last 4 quarters average of 160.3
The EPS is up by 23% since the previous quarter
KNSA's price to book (P/B) is 64% higher than its 5-year quarterly average of 3.7 and 14% higher than its last 4 quarters average of 5.3
Kiniksa Pharmaceuticals's equity has increased by 32% YoY and by 7% from the previous quarter
The stock's price to sales (P/S) is 63% less than its 5-year quarterly average of 13.3 but 8% more than its last 4 quarters average of 4.5
Kiniksa Pharmaceuticals's revenue has surged by 57% YoY and by 11% QoQ

Efficiency

How efficient is Kiniksa Pharmaceuticals business performance
Kiniksa Pharmaceuticals's return on equity has increased by 16% QoQ
Kiniksa Pharmaceuticals's return on assets has increased by 15% QoQ
KNSA's ROIC is up by 10% from the previous quarter
The return on sales is up by 8% since the previous quarter

Dividends

What is KNSA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KNSA.

Financial health

How did Kiniksa Pharmaceuticals financials performed over time
KNSA's total liabilities has surged by 55% year-on-year and by 12% since the previous quarter
The company's total assets rose by 38% YoY and by 8% QoQ
The debt is 99% smaller than the equity
The debt to equity has plunged by 50% from the previous quarter and by 50% YoY
Kiniksa Pharmaceuticals's equity has increased by 32% YoY and by 7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.